Ask about this productRelated genes to: ApoB antibody
- Gene:
- APOB NIH gene
- Name:
- apolipoprotein B
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 2p24.1
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2016-10-05
Related products to: ApoB antibody
Related articles to: ApoB antibody
- Sepsis-induced liver injury (SLI) is a severe complication of sepsis; however, its pathogenesis remains incompletely understood, and effective therapeutic agents are still lacking. - Source: PubMed
Publication date: 2026/05/28
Yu TingLiu ZhehongLiu YuGao MingGuo FazhongLiu YanjuanXiong JunJiang YuYan Shifan - Decreased hepatic removal of low density lipoproteins (LDL) and increased apolipoprotein B (apoB) production cause hypercholesterolemia, a major causal risk factor of atherosclerotic cardiovascular disease (ASCVD). By a genome-wide siRNA screen, we previously identified subunits of the Coat protein I (COPI) complex to limit LDL uptake into Huh-7 hepatocarcinoma cells. - Source: PubMed
Publication date: 2026/06/03
Panteloglou GrigoriosRobert JérômeSmit MariekeHuijkman NicoletteKloosterhuis NielsLaw Christopher SWoods BrianOthman AlaaKleber Marcus EDelgado Graciela ETarugi PatriziaLone Museer AWolters Justina ClarindaRimbert AntoineKerksiek AnjaLütjohann DieterRohrer LuciaZanoni PaoloKakava SofiaHäusler StephanieSchlumpf EvelineFutema MartaHumphries Steve EChou JanetMärz WinfriedGeha Raif SShum Anthony KKuivenhoven Jan Albertvan de Sluis Bartvon Eckardstein Arnold - : Although contemporary cardiovascular guidelines endorse intensive low-density lipoprotein cholesterol (LDL-C) lowering and advanced lipid biomarkers for refined risk stratification, important gaps in knowledge and implementation persist. This study evaluated clinician familiarity with novel lipid-lowering therapies, approaches to residual cardiovascular risk, confidence in identifying familial hypercholesterolemia (FH), and perceived usefulness of digital decision-support tools. : A multispecialty, cross-sectional online survey (October 2025) of physicians involved in dyslipidemia care was conducted. The questionnaire assessed familiarity, accessibility, and barriers regarding proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, inclisiran, and bempedoic acid; confidence and practice in managing complex populations and residual risk; confidence in detecting FH and expectations for lipoprotein(a) [Lp(a)]; and perceived value of digital decision-support and automated risk alerts. Descriptive statistics and chi-square tests were performed. : Ninety-five clinicians completed the survey, with the largest group (41.1%) being general practitioners. Of them, 20.0% reported familiarity with all three novel therapies, and 49.5% reported restricted access due to cost and reimbursement constraints. Overall confidence in managing dyslipidemia in complex populations was moderate. Of note, 31.6% did not routinely assess residual risk after achieving LDL-C targets. Among those who did, imaging-based evaluation of subclinical atherosclerosis was the most frequently selected approach, followed by Lp(a) and triglycerides, hs-CRP, and apoB. Confidence in recognizing FH was modest, and expectations regarding future Lp(a) testing differed across specialties. Most respondents endorsed integrated decision-support tools and automated risk-alert prompts. : Implementation gaps persist in dyslipidemia care, while strong receptiveness to digital decision-support highlights an opportunity to align practice more closely with evidence-based recommendations. - Source: PubMed
Publication date: 2026/05/29
Mesquita-Lousada AntónioRocha-Melo-Sousa AntóniaTeixeira CarolinaGuimarães Tiago RodriguesMarques-Vieira MárioAndrade José PauloRibeiro HugoNeiva-Sousa ManuelRocha-Neves João - Phytosterols reduce low density lipoprotein cholesterol (LDL-C) levels, supporting regulated health claims in over 10 jurisdictions. Their efficacy across different doses, matrices, and populations and on other cardiometabolic measures beyond LDL-C is unclear. We conducted a systematic umbrella review to evaluate the effects of phytosterols (plant sterols/stanols) on LDL-C and other cardiometabolic risk factors across doses, matrices, and populations, and provided an updated dose-response meta-analyses and assessment of the certainty of evidence. - Source: PubMed
Publication date: 2026/05/26
Zurbau AndreeaHaintz LukasChen VictoriaGlenn Andrea JKavanagh Meaghan EOguntala Julianah OBlanco Mejia SoniaKhan Tauseef ALeiter Lawrence AKendall Cyril W CChiavaroli LauraSievenpiper John L - Angiopoietin-like protein 3 (ANGPTL3) is a key circulating regulator of triglyceride metabolism and a promising pharmacological target. The physiological consequences of profound ANGPTL3 deficiency can be explored in individuals with inherited loss-of-function (LOF) variants, who show reduced lifetime risk of atherosclerotic cardiovascular disease. - Source: PubMed
Publication date: 2026/06/11
Arca MarcelloBjörnson EliasD'Erasmo LauraCostanzo Alessia DiBini SimoneMinicocci IleniaTramontano DanieleCovino StellaCiarlo GiuseppeLombardi ManuelaSöderlund SanniMatikainen NiinaAndersson LindaAdiels MartinTaskinen Marja-RiittaPackard Chris JBorén Jan